NEWGEN BIOPHARMA CORP

As of January 31, 2017, NEWGEN BIOPHARMA CORP carries a market capitalization of 88.52M, placing it among publicly traded companies globally. Its enterprise value stands at 88.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of January 31, 2017, NEWGEN BIOPHARMA CORP has 47.85M shares outstanding.

These figures are as of January 31, 2017.

As of January 31, 2017, NEWGEN BIOPHARMA CORP maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended January 31, 2017. Return on assets (ROA) is negative at -182.81, reflecting losses generated across the asset base.

As of the close on October 9, 2026, NEWGEN BIOPHARMA CORP's stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended January 31, 2017, NEWGEN BIOPHARMA CORP generated - - in revenue and converted that into -184,053.00 in net income, yielding earnings per share of 0.00. EBITDA reached -185,409.00, while operating income came in at -185,409.00.

These figures are as of January 31, 2017. Total book value stands at -28,646.00, with working capital of -28,646.00 providing operational flexibility.

NEWGEN BIOPHARMA CORP produced -25,226.00 in operating cash flow over the twelve months ended January 31, 2017.

These figures cover the twelve months ended January 31, 2017. Free cash flow yield is negative at -0.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.03, meaning NEWGEN BIOPHARMA CORP raised more capital through share issuance and new debt than it returned via dividends and buybacks.

NEWGEN BIOPHARMA CORP's most recent stock split took place on September 23, 2016 with a 1:4 split ratio.

As of January 31, 2017, NEWGEN BIOPHARMA CORP has an Altman Z-Score of 225.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.